Quick Answer
Zentalis Pharmaceuticals, Inc. reported Earnings Per Share Diluted of $1.91 (loss) per share for the year ending 2025.
- Zentalis Pharmaceuticals, Inc. showed an increase of +18.0% in Earnings Per Share Diluted from 2024 to 2025.
- This data is from Zentalis Pharmaceuticals, Inc.'s annual report (Form 10-K), filed with the SEC on March 26, 2026.
- XBRL data for this metric is available from 2019 to 2025 (7 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q1 2020: $2.88 (loss) per share | Q2 2020: $0.78 (loss) per share | Q3 2020: $0.91 (loss) per share | Q4 2020: $1.01 (loss) per share | Q1 2021: $1.24 (loss) per share | Q2 2021: $1.34 (loss) per share | Q3 2021: $0.09 (loss) per share | Q4 2021: $1.11 (loss) per share | Q1 2022: $1.31 (loss) per share | Q2 2022: $1.34 (loss) per share | Q3 2022: $0.96 (loss) per share | Q1 2023: $1.07 (loss) per share | Q2 2023: $1.85 (loss) per share | Q3 2023: $0.79 (loss) per share | Q1 2024: $0.14 per share | Q2 2024: $1.24 (loss) per share | Q3 2024: $0.56 (loss) per share | Q1 2025: $0.67 (loss) per share | Q2 2025: $0.37 (loss) per share | Q3 2025: $0.37 (loss) per share.
- Over the full 7 years of available data (2019 to 2025), Zentalis Pharmaceuticals, Inc.'s Earnings Per Share Diluted has grown by 76.6%.
- Historical annual values: Fiscal year 2025: $1.91 (loss) per share | Fiscal year 2024: $2.33 (loss) per share | Fiscal year 2023: $4.47 (loss) per share | Fiscal year 2022: $4.48 (loss) per share | Fiscal year 2021: $3.72 (loss) per share | Fiscal year 2020: $4.19 (loss) per share | Fiscal year 2019: $8.16 (loss) per share.
- Data sourced from SEC EDGAR public filings as of August 5, 2026.
Last verified: